Education and Counseling Checklist for Pharmacies

REVLIMID Risk Evaluation and Mitigation Strategy (REMS)™ program (formerly known as the RevAssist ® program) education and prescribing safety

Authorization No.:       Confirmation No.:       Confirmation Date:
Pharmacy Name:
Pharmacy Address:
Counselor Name:          Work Phone:          Ext.:
Patient Name:            Date of Birth:
Risk Category:

Checklist for female patients of reproductive potential

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity

☐ Not taking REVLIMID® (lenalidomide) if pregnant or breastfeeding
☐ Using **at the same time** at least 1 highly effective method—tubal ligation, IUD, hormonal (birth controls pills, hormonal patches, injections, vaginal rings, or implants), or partner’s vasectomy—and at least 1 additional effective method of birth control—male latex or synthetic condom, diaphragm, or cervical cap—**every time they have sex with a male**, or abstaining from sex with a male

☐ Continuing to use **at the same time** at least 1 highly effective method and at least 1 additional effective method of birth control beginning at least 4 weeks before taking REVLIMID, while taking REVLIMID, during dose interruptions, and for at least 4 weeks after stopping REVLIMID **every time they have sex with a male**, or abstaining from sex with a male

☐ Obtaining a pregnancy test—performed by their healthcare provider—weekly during the first 4 weeks of use. Thereafter, pregnancy testing should be repeated every 4 weeks during the rest of their treatment in females with regular menstrual cycles or no cycle at all. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks
The need to stop taking REVLIMID right away in the event of becoming pregnant, or if they think for any reason they may be pregnant, and to call their healthcare provider immediately

Possible side effects include neutropenia, thrombocytopenia, deep vein thrombosis, and pulmonary embolism as well as risk of myocardial infarction and stroke

The need for del 5q MDS patients to schedule a blood test every week for the first 8 weeks and monthly thereafter to monitor blood counts while taking REVLIMID

Not sharing REVLIMID capsules with anyone—especially with females who can get pregnant

Not donating blood while taking REVLIMID (including dose interruptions) and for 4 weeks after stopping REVLIMID

Not breaking, chewing, or opening REVLIMID capsules

Instructions on REVLIMID dose and administration

Milligram (mg) Strength_______ Number of Capsules Dispensed_______________

FEMALE CHILDREN (<18 YEARS OF AGE):

Parent or legal guardian must have read the REVLIMID REMS™ education material and agreed to ensure compliance

Checklist for female patients not of reproductive potential (natural menopause for at least 24 consecutive months, a hysterectomy, and/or bilateral oophorectomy)

I will make sure that patients are aware that they will receive the Medication Guide along with their prescription
I COUNSELED ADULTS AND CHILDREN ON:

☐ Possible side effects include neutropenia, thrombocytopenia, deep vein thrombosis, and pulmonary embolism as well as risk of myocardial infarction and stroke

☐ The need for del 5q MDS patients to schedule a blood test every week for the first 8 weeks and monthly thereafter to monitor blood counts while taking REVLIMID

☐ Not sharing REVLIMID capsules with anyone—especially with females who can get pregnant

☐ Not donating blood while taking REVLIMID (including dose interruptions) and for 4 weeks after stopping REVLIMID

☐ Not breaking, chewing, or opening REVLIMID capsules
Instructions on REVLIMID dose and administration

Milligram (mg) Strength_________ Number of Capsules Dispensed_________

FEMALE CHILDREN (<18 YEARS OF AGE):

☐ Parent or legal guardian must have read the REVLIMID REMS™ education material and agreed to ensure compliance.

☐ Parent or legal guardian must inform the child’s doctor when the child begins menses.

Checklist for male patients

☐ I will make sure that patients are aware that they will receive the Medication Guide along with their prescription.

I COUNSELED ADULTS AND CHILDREN ON:

☐ Potential embryo-fetal toxicity and contraception (wearing a latex or synthetic condom every time when engaging in sexual intercourse with a female who can get pregnant).

☐ Female partners of males taking REVLIMID® (lenalidomide) must call their healthcare provider right away if they get pregnant.

☐ Possible side effects include neutropenia, thrombocytopenia, deep vein thrombosis, and pulmonary embolism as well as risk of myocardial infarction and stroke.

☐ The need for del 5q MDS patients to schedule a blood test every week for the first 8 weeks and monthly thereafter to monitor blood counts while taking REVLIMID.
☐ Not sharing REVLIMID capsules with anyone—especially with females who can get pregnant

☐ Not donating blood or sperm while taking REVLIMID (including dose interruptions) and for 4 weeks after stopping REVLIMID

☐ Not breaking, chewing, or opening REVLIMID capsules

☐ Instructions on REVLIMID dose and administration

  Milligram (mg) Strength_______  Numbers of Capsules Dispensed_____________

MALE CHILDREN (<18 YEARS OF AGE):

☐ Parent or legal guardian must have read the REVLIMID REMS™ education material and agreed to ensure compliance
All boxes and spaces must be marked or filled in during counseling with the patient for every prescription.

Counselor Signature: ________________________ Date: _______________

For more information about REVLIMID and the REVLIMID REMS™ program, please visit www.CelgeneRiskManagement.com, or call the Celgene Customer Care Center at 1-888-423-5436.

Celgene Corporation  
86 Morris Ave  
Summit, NJ 07901

REVLIMID is only available under a restricted distribution program, REVLIMID REMS™.

Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS, enclosed.

REVLIMID® is a registered trademark of Celgene Corporation. REVLIMID REMS™ is a trademark of Celgene Corporation.

© 2014 Celgene Corporation 6/14 REMS-REV14437